# Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

> **NCT03494569** · PHASE1 · SUSPENDED · sponsor: **City of Hope Medical Center** · enrollment: 36 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia in Remission
- Hematopoietic Cell Transplantation Recipient
- Minimal Residual Disease
- Myelodysplastic Syndrome
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Fludarabine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **RADIATION:** Total Marrow Irradiation

## Key facts

- **NCT ID:** NCT03494569
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-07-06
- **Primary completion:** 2026-06-11
- **Final completion:** 2026-06-11
- **Target enrollment:** 36 (ESTIMATED)
- **Why stopped:** Accrual goal
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03494569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03494569, "Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03494569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*